Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics Authors: Quan Li, Jiancheng Hu Published: 2026 ABSTRACT AbstractLangerhans cell histiocytosis (LCH) is a nonhereditary myeloid neoplasm driven by somatic alterations in the mitogen-activated protein kinase (MAPK) signaling pathway, most commonly involving BRAF and MAP2K1 (MEK1). Oncogenic BRAF alterations activate MAPK signaling through diverse structural mechanisms. The prominent BRAF(V600E) mutation traps BRAF in a constitutively active status by forming the K507-E600 salt bridge independent of upstream RAS signaling. In contrast, non-V600E BRAF mutants exhibit variable kinase activity, among which kinase-dead variants rely on BRAF/CRAF heterodimerization and transactivate CRAF. In parallel, oncogenic MEK1 mutations disrupt autoinhibition or enhance MEK1 homodimerization, sustaining MAPK activation. Furthermore, RAF/MEK heterodimerization modulates pathway output and persistence. These mechanistic insights provide a strong biological rationale for therapeutic targeting of the MAPK pathway in LCH, thereby driving the clinical use of BRAF inhibitors (BRAFi) including vemurafenib and dabrafenib, as well as MEK inhibitors (MEKi) such as trametinib and cobimetinib. However, the efficacy is frequently limited by acquired resistance associated with MAPK pathway reactivation through RAF and MEK dimerization–dependent mechanisms. Collectively, these altered molecular interactions contribute to the pathway dysregulation and signaling persistence, thereby providing a mechanistic basis for adaptive resistance and for developing next-generation RAFi and MEKi. This review therefore summarizes the current understanding of the molecular mechanisms underlying MAPK pathway activation and therapeutic resistance in LCH, with particular emphasis on conformational switch-based regulations of RAF and MEK proteins, and discusses emerging strategies involving next-generation RAFi and RAFi plus MEKi combinations aimed to achieve more durable MAPK pathway suppression and improving long-term outcomes of LCH treatment.Keywords: Langerhans cell histiocytosis (LCH), Inflammation, BRAF, MEK, Targeted therapy Introduction Histiocytoses encompass a diverse group of rare diseases characterized by the excessive accumulation of macrophages, dendritic cells (DCs), or monocyte-derived cells in various tissues and organs, including skin, bone, spleen, liver, lung, lymph node, and central nervous system (CNS) [1]. Such cellular infiltration promotes inflammatory response and tissue injury, giving rise to a broad range of clinical manifestations depending on the specific type of histiocytoses and the extent of organ involvement. Langerhans cell histiocytosis (LCH) is the most common type of histiocytoses with an incidence rate of 4.1~8.9/million children and 1~2/million adults [2–5]. The clinical presentation of LCH is highly heterogeneous, ranging from localized single-system LCH (SS-LCH) to aggressive, life-threatening multisystem LCH (MS-LCH). Mild LCH can be limited to a single organ or system, while severe cases can lead multisystem involvement including liver, spleen, bone marrow, and CNS. If LCH is limited to the skin or single bone lesion, it may resolve spontaneously without any treatment. However, severe LCH with multisystem involvement or involving high-risk organs may require chemotherapy, surgery, radiotherapy, targeted therapies, or even bone marrow transplantation [6–8]. Despite significant advances in treatment, patients with high-risk LCH still experience disease recurrence, treatment-related toxicities, and long-term complications. Given the substantial disease burden associated with high-risk LCH, a deeper understanding of the molecular mechanisms underlying disease progression and organ damage, together with the development of more effective and less toxic therapeutic interventions, is essential to improve clinical outcomes and quality of life in patients with high-risk LCH. LCH is often linked to somatic mutations in mitogen-activated protein kinase (MAPK) pathway genes including BRAF, ARAF, MAP2K1, MAP3K1, KRAS, and NRAS [9–12]. Among these mutations, BRAF(V600E) mutation is the most prevalent, which has also been identified in a variety of cancers [11, 13–15]. In general, this mutation mimics activation loop phosphorylation that forms a salt bridge with K507 residue and locks BRAF in an active conformation [16], leading to persistent activation of downstream mitogen-activated kinase kinase (MEK)/extracellular signal–regulated kinase (ERK) signaling pathway in a dimer-dependent manner and in turn driving uncontrolled cell proliferation [17–19]. Following BRAF(V600E) mutation, MAP2K1 (encodes MEK1) alterations are the second most frequent drivers in LCH, identified in 27.5% of patients and present in nearly half of BRAF wild-type cases [20]. Recent studies have further demonstrated that dynamic rapidly accelerated fibrosarcoma protein (RAF) and MEK interactions, including BRAF/BRAF homodimers [21, 22], BRAF/CRAF heterodimers [23, 24], MEK/MEK homodimers [25], and RAF/MEK heterodimers [16], are key regulators of MAPK pathway activation. The identification of diverse RAF and MEK alterations in LCH, together with the growing recognition of dynamic RAF-MEK interactions, underscores the molecular complexity of MAPK signaling. These findings provide important insights into the mechanisms driving pathway activation and contribute to our understanding of therapeutic resistance in LCH and other MAPK-driven malignancies. In LCH, BRAF(V600E) impairs the differentiation of DC precursors and arrests them in an immature state, which causes chronic inflammatory lesions through overproducing inflammatory cytokines [26–28]. Eventually, this results in the classification of LCH as a myeloid neoplasia. It has been noted that tissue-restricted BRAF(V600E) mutation is responsible for low-risk LCH, while that in hematopoietic progenitor cells (HPCs) leads to high-risk LCH [29]. BRAF(V600E) mutation in the bone marrow HPCs promotes the clonal migration of pathogenic myeloid cells to multiple systems, driving their uncontrolled proliferation and aberrant differentiation [30–32]. The widespread distribution of BRAF(V600E) mutation in high-risk LCH also supports that this mutation occurs in an early myeloid precursor, which could explain its systemic involvement and more aggressive clinical presentation. Gaining a thorough understanding of BRAF(V600E)-driven disease progression is therefore critical for the effective management of high-risk LCH. Current therapeutic options for high-risk LCH include intensive chemotherapy and targeted therapies. Targeted therapies for LCH primarily focus on inhibiting the BRAF/MAPK pathway, which include BRAF inhibitors (vemurafenib and dabrafenib), MEK inhibitors (trametinib and cobimetinib), and their combinations. Several ongoing clinical trials that explore the potential of these inhibitors as a second-line or later treatment have shown promising outcomes in high-risk LCH with multisystem involvement [33–40]. However, these regimens have not yet been widely accepted as first-line treatment due to concerns about potential relapse after discontinuation and uncertainties regarding their long-term efficacy. Therefore, there are urgent needs for propelling targeted therapies, particularly exploring the mechanisms of drug resistance and developing new strategies capable of overcoming resistance and achieving durable remission. This review highlights the molecular mechanisms underlying LCH ontogeny and potential drug resistance in LCH treatment and discusses the development of future targeted therapeutic approaches. The classification of histiocytoses Histiocytoses are rare inflammatory myeloid neoplasms characterized by accumulation and infiltration of histiocytes in various tissues and organs. Based on the types of histiocytes involved, histiocytoses were originally classified into Langerhans cell (LC), non-LC-related, and malignant histiocytoses [41]. However, this traditional classification based on histopathological and clinical characteristics has become increasingly challenged by advances in molecular genetics. One notable example is the substantial overlap between LCH and Erdheim–Chester disease (ECD), as approximately 20% of patients with ECD also exhibit LCH lesions [42]. This coexistence suggests that these disorders may share common pathogenic mechanisms and therefore may represent different manifestations along a broader spectrum of histiocytic neoplasms rather than entirely distinct disease entities. To address these limitations and incorporate emerging molecular insights, the Histiocyte Society has endorsed a revised classification system in 2016 that consists of five different groups: Langerhans-related L group, cutaneous and mucocutaneous C group, malignant M group, Rosai–Dorfman disease of R group, and hemophagocytic lymphohistiocytosis and macrophage activation syndrome of H group [1]. This comprehensive assessment incorporates clinical, radiographic, pathological, phenotypic, genetic, and molecular features to differentiate LCH from other histiocytic disorders and to understand its diverse clinical manifestations. Among histiocytoses, LCH is the most common form, mainly affecting children under 15 years old with an incidence rate of 4.1~8.9/million [3–5]. Therefore, most current understanding of LCH comes from pediatric studies, and data on adult cases remain limited. LCH can affect various tissues throughout the body including bones (80%), bone marrow (15%), skin (33%), liver (15%), spleen (15%), lung (15%), lymph nodes (5–10%), and CNS (27–29%) [43]. As summarized in Table 1, based on the extent of organ involvement, LCH can be also categorized into SS-LCH, accounting for approximately 51.3% of cases, and MS-LCH, comprising about 48.7% [44]. SS-LCH is characterized by disease confined to a single organ or system and generally has a more favorable clinical course. In contrast, MS-LCH involves two or more organ systems and exhibits greater clinical heterogeneity, ranging from indolent disease to aggressive, life-threatening forms. Among patients with MS-LCH, the liver, spleen, and bone marrow are considered as risk organs, and their involvement significantly impacts the disease severity and treatment outcomes [43]. Given the marked differences in clinical behavior and prognosis between SS-LCH and MS-LCH, a deeper understanding of the disease-specific features is critical for developing more effective and precise treatment strategies aimed at improving outcomes for patients with high-risk MS-LCH. Table 1Classification of LCH [44]ClassificationSS-LCH (51.3%)MS-LCH (48.7%) Only one organ system affectedTwo or more organ systems affectedSubtypesUnifocal (15.9%)Multifocal (35.4%)Low risk (37.8%)High risk (10.9%)Single lesion affectedMultiple lesions affectedNo risk organs affectedRisk organs affected Classification of LCH [44] The genetic landscape of LCH LCH is considered as a nonhereditary disorder that often arises from somatic mutations on genes encoding the MAPK signaling pathway. The most common somatic mutation in LCH is BRAF(V600E), which is found in up to 69% LCH cases [45–48]. Beyond the canonical V600E mutation, a spectrum of somatic mutations has been identified in the BRAF gene including missense mutations (V600D/K, P686K, R603Q, M564V, G469A, G466R, V413M, H353R, T599A) and insertions and/or deletions (V600insDLAT, R506_K507insLLR, L505_R506insTLL, N486_P490del, L485_P490delinsF, N486_T491delinsK/S, V487_Q494delinsD) [10, 49–56]. As illustrated in Fig. 1A, in LCH, BRAF mutations predominantly occur within the conserved region 3 (CR3), a kinase domain that contains activation loop (AL), catalytic loop (CL), and phosphate-binding loop (PL). Based on their kinase activity and rat sarcoma protein (RAS) dependency, BRAF mutants are categorized into three groups: class I (V600 mutations, RAS-independent, high activity), class II (non-V600, RAS-independent, and enhanced dimer with intermediate activity), and class III (non-V600, RAS-dependent, impaired kinase activity or kinase dead) [57]. Although less frequent than point mutations, insertions, deletions, or gene fusions (FAM73A-BRAF, BICD2-BRAF, PACSIN2-BRAF, PICALM-BRAF, LMTK2-BRAF, CSF2RA-BRAF, SPPL2A-BRAF) also have been identified in LCH [55, 58–60]. A broad spectrum of BRAF alterations functionally clusters into three kinase activity-based classes with distinct RAS dependencies, underscoring the mechanistic diversity of MAPK activation in LCH. LCH-associated alterations involving BRAF and MEK1. A The molecular structure of BRAF and the distribution of mutations associated with LCH. Different colors indicate distinct types of alterations within BRAF: point mutations (red), deletions (gray), insertions (blue), and deletion/insertion alterations (green). RBD, RAS-binding domain; CRD, cysteine-rich domain; CR, conserved region; PL, P loop; CL, catalytic loop; AL, activation loop. B The molecular structure of MEK1 and the distribution of mutations associated with LCH. Different colors indicate distinct types of alterations within MEK1: point mutations (red), deletions (gray), and deletion/insertion alterations (green). EBD, ERK-binding domain; NES, nuclear export sequence; AL, activation loop; PRD, proline-rich domain; DVD, domain of versatile docking. Hotspots of MAP2K1: (I) inhibitory helix A, (II) αC-β4 loop, (III) β7-β8 loop, and (IV) β3-αC loop Furthermore, there are more than 250 non-BRAF mutations identified in LCH including genes involved in the MAPK pathway (MAP2K1, MAP2K5, MAP3K1, MAP3K9, MAP3K10, ARAF, CRAF, KRAS, NRAS, HRAS), the PI3K-AKT-mTOR pathway (PIK3CA, PIK3CD, PIK3CG, PIK3R1, AKT1, mTOR, PTEN), and the JAK-STAT pathway (JAK1, JAK3, STAT1, STAT3, STAT6), as well as their upstream activators (EGFR, HER2, HER3, HER4, FGFR2, FGFR3, ALK, CSF1R, CSF3R, FLT1, KIT, NTRK1, RET, MET), and their downstream transcription factors (TP53, TAF1, FOXO3, NFkB2, IKZF1, GATA4, GATA2, GTF2F1, E2F1) [55, 61]. Among them, alterations of MAP2K1 that encodes the MEK1 protein represent the second most prevalent genetic driver in LCH, occurring in approximately 27.5% of cases [20]. As illustrated in Fig. 1B [10, 56, 62, 63], MAP2K1 alterations are predominantly enriched within four hotspots: (I) helix A (residues 44 to 61), (II) αC-β4 loop, (III) β7-β8 loop, and (IV) β3-αC loop [25]. These alterations are functionally classified into two groups according to their activating mechanisms: helix A-associated mutants (in hotspots I, II, and III) that relieve inhibitory interactions between helix A region and kinase domain and mutants (in hotspot IV) that are in-frame deletions of the β3-αC loop, which enhance MEK1 homodimerization [25]. In addition, MEK1 mutations also can be grouped into three functional classes (classes I, II, and III) based on their dependence on upstream RAF signaling, with each cluster displaying distinct biochemical properties and therapeutic responses [64]. Class I MEK1 mutants (D67N, P124L, P124S, and L177V) induce relatively weak MEK and ERK phosphorylation, whereas class II mutants (C121S, L177M, E203K, F53L, ΔF53–Q58, Q56P, K57E, K57N, and ΔE51–Q58) preferentially enhance ERK phosphorylation. In contrast, class III mutants (ΔL98–I103, ΔE102–I103, ΔI99–K104, and ΔI103–K104) strongly activate both MEK and ERK while remaining more dependent on upstream RAF signaling. Functionally, class I and II mutants can confer acquired resistance to ERK pathway-targeted drugs including RAF and MEK inhibitors [65–67], whereas class III mutants are associated with resistance to allosteric MEK and ERK inhibitors [64, 68]. Together, these distinct biochemical and pharmacological properties underscore the functional heterogeneity of MEK1 mutations and their differential impact on MAPK pathway activation and therapeutic response. More broadly, these findings underscore the central role of aberrant MAPK signaling in LCH pathogenesis, while suggesting that the remarkable clinical and biological heterogeneity observed in LCH is driven not only by diverse alterations within the MAPK cascade but also by the interplay of additional oncogenic signaling networks. In the majority cases, LCH is thought to originate from a single oncogenic driver mutation, most frequently involving components of the MAPK signaling pathway. However, accumulating genomic evidence indicates that some patients carry multiple co-occurring mutations, which may cooperatively modify intracellular signaling networks and thereby influence disease initiation, progression, and clinical outcome (Fig. 2) [10, 53, 61, 69]. Notably, the recurrent and mutually exclusive somatic mutations identified in MAP2K1 and BRAF underscore the central role of aberrant MAPK pathway activation in LCH pathogenesis [70]. Nevertheless, emerging evidence suggests that additional signaling networks may interact with this pathway, contributing to the complexity and heterogeneity of disease biology. These interconnected signaling networks include the JNK/p38 signaling, PI3K/AKT/mTOR signaling, JAK/STAT signaling, and signalings that regulate cell cycle, proliferation, and apoptosis [10, 58, 61, 71, 72]. Additional genetic alterations in these signaling networks may further contribute to the substantial molecular and clinical heterogeneity characteristic of LCH. Identifying the comprehensive mutational landscape including the distinction between single-driver and multiple genetic alterations will not only improve risk stratification and prognostic assessment but also facilitate the development of precise therapeutic strategies and more effective long-term management. LCH mutational profile characterized by single and multiple alterations. The mutational landscape is dominated by RAF alterations in both single-mutant (39.5%) and multiple-mutant (34.9%) cases, with BRAF(V600E) representing the most frequent mutation subtype. Non-RAF alterations are less common, while other MAPK pathway mutations constitute the majority of non-RAF events Cellular and molecular pathogenesis of LCH Cellular origins and pathogenesis of LCH LCH, historically known as “histiocytosis X,” is characterized by the accumulation and proliferation of abnormal LC-like cells (LCH cells), which was originally identified by the presence of Birbeck granules and langerin/CD207 [73]. LCH cells closely resemble a pathological subset of LCs, sharing phenotypic features with normal epidermal LCs but differing fundamentally in origin and function. LCs are immature DCs residing in the skin under steady-state conditions and, despite this DC identity, share embryonic origins with tissue-resident macrophages including microglia in the brain and Kupffer cells in the liver [74, 75]. This shared and overlapping identity underscores the dual nature of LCs, exhibiting both macrophage- and DC-like properties. Such plasticity challenges traditional immune cell classification systems and supports the concept that LCH arises not simply from mature LCH transformation but from aberrant myeloid differentiation. Distinct from normal LCs, LCH cells arise from circulating mononuclear phagocytes, as well as bone marrow–derived myeloid progenitors differentiating into CD207 + cells [76–78]. These LCH cells expressing early myeloid markers can infiltrate nearly all tissues and form heterogeneous LCH lesions, as demonstrated by transcriptional profiling of cell- or tissue-specific gene expression [79–81]. In addition, genetic evidence has further strengthened the hematopoietic origin model of LCH. LCH-driver mutation, BRAF(V600E), has been detected not only in lesional tissue but also in circulating CD11C + and CD14 + fractions as well as in the HPCs from LCH patients [29]. Importantly, similar distribution patterns of mutations have been observed in cases lacking BRAF(V600E), indicating that alternative MAPK-activating mutations also arise within early hematopoietic compartments [82, 83]. These findings further suggest that LCH is a systemic disease originating from mutated progenitors within the bone marrow rather than a localized tissue disorder. The developmental stage at which these mutations occur appears to influence disease phenotype and severity. In the “misguided myeloid differentiation” model, HPCs are aberrantly directed to inappropriate sites, giving rise to high-risk MS-LCH through self-renewing, whereas low-risk MS-LCH originates from DC precursors or monocytes, and low-risk SS-LCH arises from regional DC precursors [84, 85]. This hierarchical model links cellular origin, mutation timing, and differentiation state to clinical heterogeneity, providing a coherent framework for understanding the diverse manifestations of LCH and highlighting the importance of early hematopoietic events in disease pathogenesis. Molecular mechanisms of pathogenesis LCH is an inflammatory myeloid neoplasm predominantly driven by somatic mutations in the MAPK pathway, which lead to constitutive activation of RAS/RAF/MEK/ERK cascade and result in uncontrolled proliferation and accumulation of LCH cells in tissue lesions [70]. Moreover, MAPK signaling pathways, particularly ERK, p38, and c-Jun N-terminal kinase (JNK), are crucial drivers of chronic inflammation by regulating the production of proinflammatory cytokines including tumor necrosis factor alpha (TNFα), IL-3, IL-6, IL-9, IL-10, IL-15, and IL-17, as well as chemokines including IL-8 (also known as CXCL8), CCL3, CCL7, and CXCL1 [86–89]. Indeed, abundant proinflammatory cytokines such as TNFα have been identified within LCH lesions [89, 90], suggesting that MAPK-driven cytokine production may play an important role in LCH pathogenesis. Emerging evidence also indicates that BRAF(V600E) enhances inflammatory signaling through post-transcriptional mechanisms, resulting in increased production of proinflammatory cytokines such as TNFα, thereby contributing to the inflammatory microenvironment characteristic of LCH [91]. The TNFα-triggered inflammatory signaling pathways are illustrated in Fig. 3A. Moreover, patients with LCH exhibited significantly elevated serum levels of IL-4, IL-6, IL-8, IL-10, INFγ, and CXCL1 compared with healthy controls [89, 90], implying the cross-talks among the signaling pathways driven by proinflammatory cytokines and chemokines as well as proliferative factors that have been illustrated in Fig. 3B. Inflammatory stimuli, including TNFα, IL-4, IL-6, IL-8, IL-10, INFγ, and CXCL1, activate multiple signaling pathways such as RAS/RAF/MEK/ERK, PI3K/AKT, JNK, and JAK/STAT cascades. In turn, MAPK signaling drives the transcription and secretion of IL-6 and IL-8 through downstream transcription factors. Furthermore, IL-17 induces IL-8 expression and synergizes with potent nuclear factor kappa B (NFkB) activators including TNFα, lipopolysaccharide (LPS), and interferon-gamma (IFNγ), thereby amplifying inflammatory signaling networks [92]. However, the relevance and extent of these signaling communications in LCH remain ambiguous. In LCH, the disease phenotype reflects both neoplastic and inflammatory features, contributing to its heterogeneous clinical manifestation, while cross-talks among proinflammatory stimuli and signaling pathways drive reciprocal pathway activation. These insights may provide a rationale for the development of more effective targeted therapeutic strategies for LCH, including combination approaches involving BRAFi/MEKi/ERKi and inhibitors targeting key molecules involved in inflammatory signaling as illustrated in Fig. 3. MAPK signaling pathways integrate signals from a wide range of extracellular inflammatory and proliferative stimuli. A TNFα mediates its biological effects through binding to TNFR1 and TNFR2. TNFR1 initiates the assembly of complex involving TRADD (TNFR1-associated death domain protein), which recruits TRAF2 (TNF receptor-associated factor 2) and RIPK1 to activate downstream NFkB signaling. Additionally, TRADD and RIPK1 orchestrate the FADD/caspase-mediated apoptosis, while RIPK1/RIPK3 promotes necrosis. In contrast, TNFR2 signals through TRAF1/2/3-associated complex and integrates JNK, PI3K/AKT, and NF-kB pathways. B IL-4, IL-6, IL-8, IL-10, IFNγ, and CXCL1 as well as growth factors play central roles in coordinating inflammatory and proliferative responses by engaging receptor-mediated signaling networks. RTKs and cytokine receptors transmit extracellular signals into the cell and initiate downstream cascades. IL-6 primarily signals through the JAK/STAT pathway, in addition to RAS/RAF/MEK/ERK and PI3K/AKT pathways. IL-4, IL-10, and IFNγ similarly activate JAK/STAT signaling, while IL-8 and CXCL1 signal through G-protein-coupled CXCR1/2 leading to activation of RAF/RAF/MEK/ERK and PI3K/AKT pathways BRAF(V600E) mutation is one of the most common oncogenic drivers in LCH, leading to constitutive activation of the MAPK signaling pathway. In physiological states, BRAF is folded into close monomeric conformation facilitated by cell division cycle 37 (Cdc37)/heat shock protein 90 (Hsp90) and is further locked by 14-3-3 scaffold protein. As illustrated in Fig. 4A, upon stimulation, close BRAF monomers are opened and form active side-by-side dimers with a switch of 14-3-3 binding modes [93, 94]. Active BRAF dimers then phosphorylate MEK1/2, which subsequently phosphorylate ERK1/2, leading to the activation of numerous substrates in both cytoplasm and nucleus that regulate diverse cellular processes (Fig. 4A). In addition to RAF/RAF dimerization, RAF activity also can be modulated by interactions with kinase suppressors of RAS (KSR) that heterodimerize with RAF to promote their activation through allosteric mechanisms (Fig. 4A) [95, 96]. Association of MEK with KSR promotes asymmetric BRAF/KSR heterodimerization, thereby stimulating BRAF catalytic activity toward MEK [97]. In active status, BRAF adopts an αC-helix-in and Asp-Phe-Gly (DFG)-in conformation in which Glu501 from αC-helix and K483 from VAIK motif form a salt bridge [98]. This active conformation is stabilized by BRAF dimerization, and thereby, events that improve BRAF dimerization potentially trigger its catalytic activity. For instance, mutations that disrupt Cdc37/Hsp90 chaperone association (i.e., G469A and G466R) and N-terminal fusion variants function with this mode. However, the mechanisms that stabilize the active conformation vary among different BRAF mutants. BRAF(V600E) achieves a stable active conformation through forming the Lys507-Glu600 salt bridge but not dimerization [16, 99–102], while the insertion variants of αC-β4 loop (i.e., R506_K507insLLR and L505_R506insTLL) form a large hydrophobic network to trap BRAF in active conformation [103]. Additionally, the deletion of β3-αC loop (i.e., N486_P490del, L485_P490delinsF, N486_T491delinsK/S, and V487_Q494delinsD) rotates the αC-helix as well as alters the dimer interface, which also results in a stable active conformation (Fig. 4B) [19, 104, 105]. Although their active conformation is not maintained by dimerization, these BRAF mutants phosphorylate MEK1/2 in a dimer-to-dimer manner [19]. Collectively, these oncogenic alterations shift the balance of inactive versus active conformations toward persistent BRAF activation, resulting in prolonged MEK/ERK signaling that drives oncogenic progression. This mechanistic model is also applicable to LCH, in which constitutive activation of the MAPK pathway predominantly driven by BRAF(V600E) has been implicated in disease pathogenesis. Functional dynamics of BRAF V600E, non-V600E, and wild-type variants in the regulation of the RAF/RAF/MEK/ERK signaling pathway. A Under physiological conditions, wild-type BRAF activation is dependent on upstream RAS-GTP signaling, which promotes RAF membrane recruitment and formation of BRAF dimers. Beyond homodimerization, BRAF also forms heterodimers with CRAF. Owing to its relatively strong dimer affinity and unique N-terminal acidic motif, BRAF can efficiently transactivate CRAF within dimer complex. RAS-dependent signaling is important under physiological conditions, where it promotes BRAF/CRAF heterodimer formation. In parallel, CRAF can also form CRAF/CRAF homodimers. Additionally, the CDC37/Hsp90 chaperone complex plays a critical role in maintaining the conformational stability of RAF. As an important allosteric activator, KSR facilitates the efficient assembly and interaction of RAF, MEK, and ERK signaling components and contributes to the MAPK pathway activation. MEK/MEK dimerization has been implicated in regulating downstream ERK signaling, while RAF and MEK interact through transient kinase-substrate complexes during signal transduction. B BRAF(V600E) mutation stabilized the kinase in an active conformation through a strong salt bridge even in the absence of upstream RAS activation. However, BRAF non-V600E mutations exhibit a spectrum of kinase activities through their intrinsic catalytic properties. In addition, kinase-dead BRAF variants can still contribute to MAPK pathway activation through their ability to promote dimerization with CRAF, thereby facilitating CRAF-mediated signaling activation In addition, MAP2K1 alterations have been identified in approximately 50% cases with wild-type BRAF in LCH lesions [20], further supporting the central role of the MAPK pathway in LCH pathogenesis. Cancer-associated alterations in MAP2K1 relieve intramolecular autoinhibition or directly enhance homodimerization [25], which facilitates intradimer cross-phosphorylation of the activating loop of MEK1, promoting sustained kinase activation. This mechanism maintains MEK1 activity downstream of RAF, thereby contributing to persistent MAPK pathway activation [25]. Moreover, BRAF/MEK1 heterodimerization functions as a regulatory node that is sensitive to MEK1 phosphorylation and can be modulated independently of BRAF kinase activity [16]. This is proven by conformation-specific BRAF inhibitors that trap a dormant BRAF/MEK1 complex and thereby lead to suppression of downstream MAPK signaling [16, 106, 107]. Collectively, these observations extend the concept that MAPK pathway output is governed not only by MEK1 homodimerization-driven catalytic amplification but also by dynamic regulation of BRAF/MEK1 complex formation (Fig. 4), highlighting multiple structurally distinct hubs that can be exploited for therapeutic intervention. Given alterations of BRAF and MAP2K1 in more than 80% of LCH patients [108], a deeper understanding of the molecular mechanisms governing BRAF and MEK1-mediated MAPK signaling pathway activation is essential for developing appropriate therapeutic strategies. Such insights may facilitate the design of more effective targeted agents, rational combination therapies, and treatment approaches capable of achieving durable MAPK pathway suppression and overcoming resistance associated with pathway reactivation in current LCH treatment. Current therapies and future treatment strategies of LCH LCH treatment is tailored according to disease classification, risk stratification, and the underlying molecular alterations. For patients with SS-LCH and low-risk MS-LCH, standard first-line therapy typically consists of combination chemotherapy with vinblastine and prednisone [109], which aims to control disease progression and reduce inflammatory burden. In contrast, patients with high-risk MS-LCH, particularly those harboring driver mutations in BRAF such as BRAF(V600E), or alterations in MAP2K1 and other MAPK pathway genes may benefit from treatment with BRAF, MEK, and ERK inhibitors, which directly inhibit aberrant signaling, offering improved disease control and outcomes in refractory or high-risk cases. The integration of molecular profiling into clinical decision-making has shifted LCH management from a purely risk-adapted approach toward a precision medicine framework, in which treatment selection is increasingly guided by both disease severity and pathogenesis driven by MAPK pathway alterations. In Nov. 2017, the US Food and Drug Administration (FDA) granted approval to vemurafenib, a BRAF selective inhibitor, for treating ECD, in which concomitant occurrence of LCH has been reported in approximately 15% of patients [110]. However, quick-rising drug resistance limits its clinical benefit, leading to only transient disease control. To address this limitation, next-generation inhibitors that target both protomers in a BRAF dimer or all RAF isoforms have been developed and are progressing through clinical evaluation [111]. As summarized in Table 2 [22], type I½ (αC-out/DFG-in) inhibitors (vemurafenib, dabrafenib, and encorafenib) primarily target BRAF(V600E), while Plx7904 and plixorafenib exhibit equipotent activity against both BRAF(V600E) and its variants with enhanced dimerization. Further advances have led to the development of type II (αC-in/DFG-out) inhibitors, which bind distinct conformations and generally exhibit greater activity against RAF dimers. Regorafenib, belvarafenib, and related compounds display preferential affinity for enhanced RAF dimers, whereas ponatinib, tovorafenib, and related compounds demonstrate more balanced activity against both weak and strong RAF dimers. Overall, while the efficacy of early RAF inhibitors represented a major advance in the treatment of MAPK-driven LCH, their efficacy is compromised by pathway reactivation or switch. The development of next-generation RAF inhibitors with improved activity against enhanced RAF dimers or multiple RAF isoforms represents a promising strategy to overcome these limitations and improve the durability of clinical responses in LCH and related histiocytic neoplasm. Table 2BRAFi classification and their development stages [22]TypeαC/DFGSelectivityInhibitorIC50 (nM)aK-E (Å)CompanyHighest statusI½Out/inVemurafenib9.911.5GenentechFDA approvedMonomerDabrafenib0.77.4NovartisFDA approvedEncorafenib0.4-PfizerFDA approvedEquipotentPlx79044.27.5PlexxikonPreclinicalPlixorafenib3.8-ForeBTDIIIn/outDimerRegorafenib19.0-BayerFDA approvedSorafenib38.02.6BayerFDA approvedNaporafenib51.33.0NovartisFTDBelvarafenib13.32.7GenentechPhase 2 trialRAF7091.02.8ArrayPreclinicalPHI110.02.5Albert Einstein College of MedPreclinicalEquipotentPonatinib14.03.0TakedaFDA approvedTovorafenib7.12.5Day OneFDA approvedLifirafenib23.05.5BeiGenePhase 2 trialLY30091207.82.7Eli LillyPhase 1 trialAZ6287.23.0AstraZenecaPreclinicalTAK6322.43.0TakedaPreclinicalIC50 values for vemurafenib, dabrafenib, sorafenib, tovorafenib, and encorafenib were obtained from US FDA reports. IC50 values for regorafenib [113], naporafenib [114], belvarafenib [114], LY3009120 [114], AZ628 [114], RAF709 [115], ponatinib [115], PHI1 [115], lifirafenib [116], and TAK632[117] were extracted from the corresponding published references. IC50 values for Plx7904 and Plx8394 (plixorafenib) were obtained from patent application WO201691296A1aKinase assay to BRAF(V600E) BRAFi classification and their development stages [22] IC50 values for vemurafenib, dabrafenib, sorafenib, tovorafenib, and encorafenib were obtained from US FDA reports. IC50 values for regorafenib [113], naporafenib [114], belvarafenib [114], LY3009120 [114], AZ628 [114], RAF709 [115], ponatinib [115], PHI1 [115], lifirafenib [116], and TAK632[117] were extracted from the corresponding published references. IC50 values for Plx7904 and Plx8394 (plixorafenib) were obtained from patent application WO201691296A1 aKinase assay to BRAF(V600E) Beyond BRAFi, targeting downstream MEK signaling has emerged as an important therapeutic strategy for LCH. In Nov. 2022, FDA approved a selective MEKi, cobimetinib, for the treatment of histiocytic neoplasm including LCH, further validating MAPK pathway inhibition as an effective therapeutic approach. In addition, although dabrafenib or trametinib monotherapy has not received FDA approval for the treatment of LCH, both agents are widely used off-label in clinical practice due to their substantial therapeutic efficacy and clinical outcomes in patients with MAPK-driven LCH. Accumulating clinical evidence has demonstrated that inhibition of the BRAF/MEK/ERK signaling axis can induce rapid and durable responses, particularly in patients harboring BRAF and MAP2K1 mutations. A major milestone in the development of targeted therapy for LCH and related MPAK-driven malignancies occurred in Jun. 2022, when the FDA granted approval for the combination therapy of dabrafenib and trametinib for the treatment of BRAF(V600E)-mutant solid tumors including LCH. This approval highlighted the growing shift toward precision oncology, where treatment decisions are guided by the presence of actionable molecular alterations rather than the tissue of origin. As summarized in Table 3, BRAFi and MEKi have now received regulatory approval across a broad spectrum of malignancies, providing an expanding repertoire of targeted agents that may be applicable to LCH. Indeed, several clinical trials of LCH are currently in progress, which are investigating the targeted therapies using BRAFi (vemurafenib, dabrafenib) and MEKi (trametinib, cobimetinib), as well as ERKi (ulixertinib) as a second-line or later treatment in patients with high-risk MS-LCH (Table 4). These studies aim to further define the efficacy, safety, and optimal treatment strategies for incorporating targeted therapies into LCH management. Despite these advances, significant clinical challenges remain. Acquired resistance frequently develops through mechanisms such as MAPK pathway reactivation, resulting in disease recurrence despite initial responses. Table 3FDA-approved BRAFi and MEKiDrug nameTargetCompanyApproved onDiseaseVemurafenibBRAFGenentech2011-08-17Late-stage skin cancer2017-11-06ECD with BRAF mutationPonatinibBRAFTakeda2012-12-14CML and Ph + ALLDabrafenibBRAFNovartis2013-05-29Advanced melanomaEncorafenibBRAFPfizer2018-06-27Melanoma with BRAF mutationsTovorafenibBRAFDay One2024-04-23BRAF-altered pediatric low-grade gliomaTrametinibMEK1/2Novartis2013-05-29Advanced melanomaCobimetinibMEK1/2Genentech2015-02-18Advanced melanoma2022-11-01Histiocytic neoplasmsBinimetinibMEK1/2Array2018-06-27Melanoma with BRAF mutationsSelumetinibMEK1/2AstraZeneca2020-04-13Neurofibromatosis type 1MirdametinibMEK1/2SpringWorks2025-02-11Neurofibromatosis type 1Dabrafenib + trametinibBRAF + MEK1/2Novartis2014-01-09Melanoma with BRAF mutations2022-06-23BRAF(V600E) solid tumors including LCHVemurafenib + cobimetinibBRAF + MEK1/2Genentech2015-11-10Advanced melanoma FDA-approved BRAFi and MEKi Table 4Clinical trials of targeted therapy in LCHInterventionTargetTrial numberPhaseStart dateStatusOutcomeVemurafenibBRAFNCT02205762Phase 2/32016-11Completed Donadieu et al., 2019 [34] VemurafenibBRAFNCT03220035Phase 22017-11Completed Nelson et al., 2024 [118] VemurafenibBRAFNCT03585686Phase 22018-06Completed Evseev et al., 2023 [119] VemurafenibBRAFNCT03155620Phase 22017-07OngoingNAVemurafenibBRAFNCT04943198Phase 22021-04OngoingNADabrafenibBRAFNCT01677741Phase 1/22013-05Completed Whitlock et al., 2023 [38] HLX208BRAFNCT05092815Phase 22021-12CompletedCao et al., ASCO 2023TrametinibMEK1/2NCT04943224Phase 22021-04OngoingNATrametinibMEK1/2NCT06582745Phase 22024-06OngoingNACobimetinibMEK1/2NCT02649972Phase 22016-01Completed Diamond et al., 2019 [74] CobimetinibMEK1/2NCT04079179Phase 22021-04OngoingNALuvometinibMEK1/2NCT05997602CTR20232238Phase 22023-09OngoingZhang et al., EHA 2025MirdametinibMEK1/2NCT06153173Phase 22024-02OngoingNAUlixertinibERK1/2NCT03698994Phase 22018-11CompletedTran Vo et al., ASCO 2022Dabrafenib + trametinibBRAF + MEK1/2NCT02124772Phase 1/22015-01Completed Whitlock et al., 2023 [38] Dabrafenib + trametinibBRAF + MEK1/2NCT07440290Phase 2/32026-02Not yet recruitingNATrametinib/dabrafenibMEK1/2/BRAFNCT07022834Phase 22025-06OngoingNATrametinib + adebrelimabMEK1/2 + PD-L1NCT06902792Phase 12025-02OngoingNAInformation was extracted from ClinicalTrials.gov Clinical trials of targeted therapy in LCH NCT05997602 CTR20232238 Information was extracted from ClinicalTrials.gov Conclusions and future perspectives Although conventional chemotherapy remains an important component of treatment, response in high-risk MS-LCH patients is variable, and disease relapse is common. Thus, patients with high-risk MS-LCH represent a challenging clinical population that often require more intensive and precise treatment approaches due to the higher likelihood of multisystem involvement and organ dysfunction. These patients respond less predictably to conventional chemotherapy alone and therefore are increasingly managed with risk-adapted strategies that incorporate targeted therapies, particularly in cases harboring MAPK pathway alterations such as BRAF(V600E). Accumulating evidence has confirmed that somatic alterations in the MAPK signaling pathway cause LCH, a nonhereditary myeloid neoplasm. Particularly, oncogenic BRAF alterations activate MAPK signaling through diverse structural mechanisms that stabilize active conformation directly or improve BRAF/BRAF homodimer and BRAF/CRAF heterodimer formation, while oncogenic MAP2K1 mutations relieve intramolecular autoinhibition or enhance homodimerization, leading to the activation of persistent MAPK signaling (Fig. 4). These insights into the structural and functional consequences of BRAF and MEK1 alterations provide a strong clue for therapeutic targeting of MAPK pathway in LCH, which has translated into the clinical use of BRAFi and MEKi. Despite initial clinical efficacy, responses to BRAFi are frequently limited by the emergence of acquired resistance, commonly driven by adaptive reactivation of the MAPK signaling. This reactivation often occurs through RAF and MEK dimerization–dependent mechanisms, which restore downstream ERK signaling even in the presence of upstream kinase inhibition. These limitations underscore the need for therapeutic strategies targeting multiple levels of MAPK pathway. For example, ERK inhibitors directly target the downstream effector kinase and may overcome acquired resistance to MEK inhibitors, as well as combined BRAF and MEK inhibitors [112]. Given their reduced susceptibility to upstream resistance mechanisms, ERK inhibitors, particularly in combination with upstream RAF/MEK inhibitors, represent a promising strategy for achieving sustained pathway suppression. To further overcome RAFi resistance, the next-generation therapeutic strategies have been designed to effectively prevent pathway reactivation, which include advanced RAFi with improved dimer-targeting properties, as well as combination regimens integrating RAF, MEK, and ERK inhibition to achieve sustained pathway suppression. In addition to constitutive MAPK activation, extensive cross-talks among proinflammatory stimuli and intracellular signaling pathways sustain both inflammation and disease progression of LCH. As illustrated in Fig. 3, inflammatory stimuli activate multiple signaling pathways that shape inflammatory microenvironment, highlighting key inflammatory molecules as potential complementary therapeutic targets, particularly for patients with persistent inflammation despite MAPK pathway suppression. In parallel, targeted protein degradation strategies, including proteolysis-targeting chimeras (PROTACs), represent an emerging therapeutic approach with potential relevance to LCH by enabling selective degradation of oncogenic MAPK pathway components rather than merely inhibiting their catalytic activity. Such strategies may offer an alternative approach of achieving more sustained pathway suppression and potentially overcoming adaptive signaling mechanisms that limit the efficacy of conventional kinase inhibitors. Collectively, therapeutic approaches targeting both oncogenic MAPK signaling and inflammatory pathways, together with emerging protein degradation technologies, may provide opportunities for more comprehensive and durable disease control in LCH. These ongoing advances would lead to prolonged clinical benefit and enhance long-term disease control of LCH in future. Acknowledgements The authors gratefully acknowledge the use of PubMed, ClinicalTrials.gov, and Drugs.com as valuable resources for literature retrieval, clinical trial information, and drug approval data. Abbreviations Activation loop BRAF inhibitor Cell division cycle 37 Catalytic region Central nervous system Conserved region Cysteine-rich domain Dendritic cells Deletion Deletion-insertion Asp-Phe-Gly Erdheim–Chester disease Extracellular signal–regulated kinase Food and Drug Administration Hematopoietic progenitor cells Heat shock protein 90 Interferon-gamma Insertion C-Jun N-terminal kinase Kinase suppressors of RAS Langerhans cell Langerhans cell histiocytosis LC-like cells Lipopolysaccharide Mitogen-activated protein kinase Mitogen-activated kinase kinase MEK inhibitor Multisystem LCH Nuclear factor kappa B Phosphate-binding loop Proteolysis-targeting chimeras Rapidly accelerated fibrosarcoma protein RAF inhibitor Rat sarcoma protein RAS-binding domain Receptor tyrosine kinase Single-system LCH Tumor necrosis factor alpha TNFR1-associated death domain protein TNF receptor-associated factor Author contributions Q.L. and J.H. established the central concept of the review, defined the search terms, performed critical revision of this review article, and approved the final manuscript. Q.L. created the figures and tables, and wrote the paper. Funding This work was supported by Ministry of Health Singapore grant OFIRG21nov-0091 (JH), Ministry of Health Singapore grant OFIRG23jan-0079 (JH), SingHealth Foundation grant AM/TP096/2025 (QL), and Asian Foundation for Cancer Research grant AFCR-2017/2019-JH (JH). Data availability No datasets were generated or analyzed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication The authors confirm their consent to publish the manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Quan Li, Email: li.quan@nccs.com.sg. Jiancheng Hu, Email: Jiancheng.hu@duke-nus.edu.sg. References Associated Data Data Availability Statement No datasets were generated or analyzed during the current study.